1. Home
  2. ZKH vs ENTA Comparison

ZKH vs ENTA Comparison

Compare ZKH & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZKH

ZKH Group Limited

HOLD

Current Price

$3.20

Market Cap

486.5M

Sector

N/A

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$14.51

Market Cap

407.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKH
ENTA
Founded
1998
1995
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
486.5M
407.5M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
ZKH
ENTA
Price
$3.20
$14.51
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$20.40
AVG Volume (30 Days)
211.9K
288.8K
Earning Date
11-20-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,236,195,501.00
$65,324,000.00
Revenue This Year
$2.44
$0.99
Revenue Next Year
$9.14
$0.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$4.09
52 Week High
$4.03
$15.34

Technical Indicators

Market Signals
Indicator
ZKH
ENTA
Relative Strength Index (RSI) 53.96 72.93
Support Level $2.93 $11.89
Resistance Level $3.49 $14.52
Average True Range (ATR) 0.18 0.86
MACD 0.02 0.10
Stochastic Oscillator 48.67 95.27

Price Performance

Historical Comparison
ZKH
ENTA

About ZKH ZKH Group Limited

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: